They choose that the blood test can get Expand to a decade in 10 years in 10 years as first symbols -

Identifying a plasma headache to 98% of the natural intelligence in Europe and the United States, 98%

First Sclerosis Symptoms (Ela) Leave before the patient and the classic signals of doctors.

It appears through the study was published in the medicine conditions, which is identified the setup of blood, which has the ability to expect harmed until ten years before the main diagnosis.

Finding can be the most important step in the original pathology test consisting of an annual strike between 3.5 and 2.7 new cases every 100,000.

ELA is a disease of the nervous system that weakens the muscles and affects mobility, speech, food and breathing. The diagnosis usually comes when these symptoms have already been installed.

Today, with this vision, researchers at the National Health University and the University of Johns Hopkins, and the University of Turin, repair equipment that can distinguish healthy and healthy people.

ELA: past, questions, and new research methods

Had already known that ela causes the injury to progress to Momor and Euroins, but the amazing symptoms of mind for mental.

Although the nefl protein in the cerebrospinal fluid is already used as a possible marker, the available tests have not offered sufficient precision of a standard blood analysis.

The main purpose of the United States and its vustralla then finds a blood protein that works to work as the first notice.

For this reason, he resorted to the use of artificial intelligence devices and analyzed about three thousand levels of protein in plasma samples.

Information from the devastating patients as well as those at risk or committed.

The limits of lessons about minor lessons about minor features and small things.The study study is recorded in this directive to the skill in Italian letters, seeing from English and the English center and average centers.

One of the main challenges was to distinguish Ila from another neuromuscular disorder: "The model managed to distinguish the same diseases with more than 99%sensitivity," he said.

It has been processed automatically and showing the ability to distinguish between symptoms and previews of a healthy control patients.

"The world of protein can serve in the beginning of the long, ananihogi with Alzheimer's disease," they said.

Here are the Bowers detected

Scientists analyzed patients in blood, healthy controls and people with other neurological diseases.

They have applied technology, which allow you to measure thousands of viruses in an instance of a check.Advanced with artificial intelligence tools to identify the behavioral groups of you.

One of the main findings of the confirmation was that the north protein and the other sixteen would load their values ​​long before the obvious symptoms appear.

"Ten years ago, the risk marks of the risk marks in ten years ago ten years ago in ten years ago," said Ela.

Biomolicular comparison depends on more than just years or genetics.

They realized the main restriction to measure about 3000 protein in current experiments, so there may be other relevant molecules far from these platforms.

In addition, it was not available to read all four appearances or evaluated in detail that affects people with national groups.

Therefore, they think that exams should be expanded in larger number of groups in future research.

One limit is lying below the amount of cerebrospinpinal fluid samples, a fluid indicating changes to the average nervous system.

Changes identified in the blood coincide in several biomarkers with changes observed in this fluid.

The panel continues to recommend that the two types of forms are collected and expanding therapeutic tests before considering a large test.

In dialogue with, Alejandro Köhler, a neurologist and coordinator of the Ela Clinic in Funi, said in Buenos Aires, Argentina, after reading the study: "This new work is published in Natural Medicine highlighting that health professionals can approach the diagnosis of previous diseases, when using Simple blood."

The results of the study could also allow people to control people who are at risk of some mutations.

"Of course, the tool still requires it to be evaluated in other populations," Köhler acknowledges. "However, as a concept proof, it is an important step for an early diagnosis within the framework of precision medicine."